The approach to the patient with a difficult melanocytic lesion

References

• Antonescu CR, Tschernyavsky Si, Woodruff JM, Jungbluth AA, Brennan MF, Ladanyi M. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopatholo-gical and ultrastructural analysis of 12 cases. J Mol Diagn 2002; 4: 44–52.
   PubMed Web of Science ®Google Scholar
• Foucar E. Diagnostic decision-making in anatomic pathology. Am J Gun Pathol 2001; 116 (Suppl): S21–33.
   Google Scholar
• Bastian BC. Molecular cytogenetics as a diagnostic tool for typing melanocytic tumors. Recent Results Cancer Res 2002; 160: 92–9.
   PubMedGoogle Scholar
• Brenner H. How independent are multiple 'independent' diagnostic classifications? Stat Med 2004; 15: 1377–86.
   Web of Science ®Google Scholar
• Cerroni L, Kerl H. Tutorial on melanocytic lesions. Am J Dermatopathol 2001; 23: 237–41.
   PubMedGoogle Scholar
• Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999; 30: 513–20.
   PubMed Web of Science ®Google Scholar
• Lasota J, Dansonka-Mieszkowska A, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003; 16: 1257–64.
   PubMed Web of Science ®Google Scholar
• Lee AH, Denley HE, Pinder SE, et al. Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). Histopathology 2003; 42: 331–6.
   PubMed Web of Science ®Google Scholar
• Marion-Audibert AM, Barel C, Gouysse G, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125: 1094–104.
   Google Scholar
• Moore SW, Satge D, Sasco Ai, Zimmermann A, Plaschkes J. The epidemiology of neonatal tumours. Report of an international working group. Pediatr Surg Int 2003; 19: 509–19.
   PubMed Web of Science ®Google Scholar
• Folpe AL, Fanburg-Smith JC, Miettinen M, Weiss SW. Atypical and malignant glomus tumors: analysis of 52 cases, with a proposal for the reclassification of glomus tumors. Am J Surg Pathol 2001; 25: 1–12.
   PubMed Web of Science ®Google Scholar
• Medina Perez M, Valero Puerta JA, Perez Martin D. Atypical stromal hyperplasia of the prostate (stromal proliferation of uncertain malignant potential). (Spanish.) Arch Esp Urol 2000; 53: 722–3.
   PubMedGoogle Scholar
• Nucci MR, Prasad CJ, Crum CP, Mutter GL. Mucinous endometrial epithelial proliferations: a morphologic spectrum of changes with diverse clinical significance. Mod Pathol 1999; 12: 1137–42.
   PubMed Web of Science ®Google Scholar
• Lin BT, Bonsib SM, Mierau GW, Weiss LM, Medeiros Li. Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol 1998; 22: 603–14.
   Google Scholar
• Menaker GM, Sanger JR. Granular cell tumor of uncertain malignant potential. Ann Plast Surg 1997; 38: 658–60.
   PubMed Web of Science ®Google Scholar
• Soumakis S, Panayiotides J, Protopapa E, Kouri E, Vlachonikolis J, Delides GS. Quantitative pathology in uterine smooth muscle tumours: the case for the standard histologic classification criteria. Eur J Gynaecol Oncol 1997; 18: 203–7.
   PubMed Web of Science ®Google Scholar
• Carr Ni, Sobin LH. Unusual tumors of the appendix and pseudomyxoma peritonei. Semin Diagn Pathol 1996; 13: 314–25.
   PubMed Web of Science ®Google Scholar
• Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000; 157: 967–72.
   Google Scholar
• Foucar E. Debating melanocytic tumors of the skin: does an 'uncertain' diagnosis signify borderline diagnostic skill? (Letter.) Am J Dermatopathol 1995; 17: 626–34.
   PubMed Web of Science ®Google Scholar
• Sackett DL, Haynes RB, Tugwell P. Early diagnosis. In: Sackett DL, Haynes RB, Tugwell P, editors. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown & Company, 1985; 139–55.
   Google Scholar
• Ackerman AB, Briggs PL, Bravo F. Dysplastic nevus, compound type vs. Clark's nevus, compound type. In: Ackerman AB, Briggs PL, Bravo F, editors. Differential Diagnosis in Dermatopathology IIL Philadelphia: Lea and Febiger, 1993; 158–61.
   Google Scholar
• Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439–44.
   Google Scholar
• Arumi-Uria M, McNutt NS, Finnerty B. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003; 16: 764–71.
   Google Scholar
• Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986; 123: 195.
   Google Scholar
• Sun J, Morton TH, Gown AM. Antibody HMB-45 identifies the cells of blue nevi. Am J Surg Pathol 1990; 14: 748–51.
   Google Scholar
• Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996; 27: 528–31.
   Google Scholar
• Piepkorn MW, Barnhill RL, Cannon-Albright LA, et al. A multi-observer, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol 1994; 30: 707–14.
   Google Scholar
• Weinstock MA, Barnhill RL, Rhodes AR, Brodsky GL. Reliability of the histopathologic diagnosis of melanocytic dysplasia. The Dysplastic Nevus Panel. Arch Dermatol 1997; 133: 953–8.
   PubMedGoogle Scholar
• McDermott NC, Hayes DP, al-Sader MH, et al. Identification of vertical growth phase in malignant melanoma. A study of inter-observer agreement. Am J Clin Pathol 1998; 110: 753–7.
   Google Scholar
• Cook MG, Clarke Ti, Humphreys S, et al. A nationwide survey of observer variation in the diagnosis of thin cutaneous malignant melanoma including the MIN terminology. J Clin Pathol 1997; 50: 202–5.
   PubMed Web of Science ®Google Scholar
• Wolinsky S, Silvers DN. The small lentiginous nevus. Am J Dermatopathol 1985; 7 (Suppl): 5–11.
   Google Scholar
• Rivers JK, McCarthy SW, Shaw HM, Jones AS, Glasziou P, Doran Ti, McCarthy WH. Patients with thick melanomas surviving at least 10 years: histological, cytometric and HLA analyses. Histopathology 1991; 18: 339–46.
   Google Scholar
• Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 2003; 22: 3081–6.
   PubMed Web of Science ®Google Scholar
• McArdle L, Bergin O, Fallowfield ME, Dervan PA, Easty DJ. Tyrosine phosphate in melanoma progression. Br J Dermatol 2003; 149: 289–95.
   PubMed Web of Science ®Google Scholar
• Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993; 68: 4–17.
   PubMed Web of Science ®Google Scholar
• Elder DE, Rodeck U, Thurin J, et al. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 1989; 49: 5091–6.
   PubMed Web of Science ®Google Scholar
• Elder DE, Guerry D, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984; 6 (Suppl): 55–61.
   Google Scholar
• Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13: 389–96.
   PubMed Web of Science ®Google Scholar
• McGinnis KS, Lessin SR, Elder DE, et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol 2002; 138: 617–21.
   PubMedGoogle Scholar
• Thorn M, Ponten F, Johansson AM, Bergstrom R. Rapid increase in diagnosis of cutaneous melanoma in situ in Sweden, 1968-1992. Cancer Detect Prey 1998; 22: 430–7.
   PubMedGoogle Scholar
• National Institutes of Health National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29,1992. Am J Dermatopathol 1993; 15: 34–43.
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong Si, et al. New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003; 21: 43–52.
   PubMedGoogle Scholar
• Dessureault S, Soong Si, Ross MI, et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001; 8: 766–70.
   PubMed Web of Science ®Google Scholar
• Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer 2003; 97: 499–507.
   Google Scholar
• Kelley SW, Cockerell CJ. Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: a proposal. J Am Acad Dermatol 2000; 42: 527–30.
   PubMed Web of Science ®Google Scholar
• Mihic-Probst D, Zhao J, Saremaslani P, Baer A, Komminoth P, Heitz PU. Spitzoid malignant melanoma with lymph-node metastasis. Is a copy-number loss on chromosome 6q a marker of malignancy? Virchows Arch 2001; 439: 823–6.
   Google Scholar
• Smith KJ, Barett TL, Skelton HG, Lupton GP, Graham JH. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz tumor). Am J Surg Pathol 1989; 13: 931–9.
   Google Scholar
• Temple-Camp CR, Saxe N, King H. Benign and malignant cellular blue nevus. A clinicopathological study of 30 cases. Am J Dermatopathol 1988; 10: 289–96.
   Google Scholar